Fairtility unveils CHLOE OQ™ expanding its offering into fertility preservation

Fairtility, the transparent AI innovator powering reproductive care for improved outcomes, has announced the launch of CHLOE OQ™, bringing Oocyte Quality Insights to CHLOE’s core technology suite of capabilities and expanding the applicability of its AI-driven decision support tool to fertility preservation.

The solution will be unveiled at the 39th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) being held in Copenhagen, Denmark from June 25 to 28, 2023.

With CE declared for CHLOE OQ™, the new Oocyte Quality Insights capability offers IVF professionals comprehensive information to support decision making as patients undergo fertility preservation or assisted reproductive journeys.

The tool delivers predictions of an oocyte’s potential to reach the blastocyst stage post-fertilisation.

“Assessing fertility potential involves understanding three factors: sperm, oocytes and embryos. We can evaluate the viability of embryos and understand sperm quality. However, assessing oocyte quality has remained a statistical gamble,” said Dr Cristina Hickman, chief clinical officer of Fairtility.

“When looking at a seemingly ‘good’ oocyte, we can’t really identify which one will become a blast after fertilisation. CHLOE OQ helps us fill the critical gap, providing evidence-based viability predictions for the evaluation of oocytes.

“This will help clinicians to provide transparency to patients while discussing a failed IVF cycle in fertility preservation, or when assessing and allocating donor eggs.”

Oocyte quality assessment commonly relies on statistical methods based on a woman’s age. Embryologists analyse oocyte quality based on oocyte maturity and characteristics including size, texture, shape, discoloration and fragmentation.

However, these factors have proven to be subjective and lack correlation with the actual quality of the egg.

CHLOE OQ brings the power of AI to oocyte assessment, replacing generalised decision-making with personalised, data-driven AI analysis that reveals the potential of each oocyte backed by biological data.

CHLOE OQ offers personalised data to support decision making for three key applications:

• Egg freezing: In the process of fertility preservation, IVF professionals may recommend an additional oocyte retrieval based on the raw number of oocytes retrieved. While CHLOE OQ cannot change the biology of the egg, it can assist in providing a personalised assessment and managing expectations for family planning early on. CHLOE OQ helps IVF professionals and patients make informed decisions on whether to undergo an additional oocyte retrieval cycle. The tool is designed to optimise the chances of successful IVF in the future and gives women greater control of their reproductive opportunities later in life.
• Egg donation: CHLOE OQ helps fertility clinics and egg banks to further assess the quality of donor eggs, ensuring equitable distribution to recipients. By leveraging data-driven insights, donor-egg providers may match recipients with the most suitable donor eggs, increasing the chances of successful IVF outcomes, maximising limited donor egg resources and enhancing the donor-recipient experience.

• IVF treatment: During IVF, older patients are often guided to utilise donor eggs based on age rather than the true quality of their eggs. At 40-years of age, approximately 10 per cent of patients utilise their own eggs, and by 44-years old, this number drops to one per cent. CHLOE OQ is expected to help IVF professionals consider if a patient’s own eggs have sufficient quality for a successful IVF treatment, or if an egg donor may be a more suitable option. This reduces costs for patients undergoing IVF and maximises egg donor resources. A better understanding of oocyte quality also provides IVF professionals insight on an oocyte’s role in a failed IVF cycle, enabling better treatment decisions for future IVF cycles.

“Adding oocyte analysis broadens CHLOE’s core technology capabilities, extending beyond embryo assessment for IVF. CHLOE OQ now provides decision support for fertility preservation, egg donation, and female-factor infertility in IVF treatment. This expansion allows us to assist a larger population seeking to secure their reproductive futures,” stated Eran Eshed, CEO and co-Founder of Fairtility.

“While we can’t halt the passage of time and the consequent decline in oocyte quality, we can effectively freeze it. With CHLOE OQ, patients, through their fertility care team, can gain transparency into their oocytes’ viability, enabling proactive management of their reproductive health and facilitating well-informed decisions based on biological data.”

CHLOE’s core technology is the first and only decision support tool that combines AI-driven analysis of embryos and oocytes with explainable biological insights in terms that IVF professionals understand and can trust.

This supports data-driven and consistent decision-making in the IVF lab, with a goal of optimising outcomes, making fertility care more efficient and creating new family-building possibilities.